March 17, 2023
2 min watch
Save
VIDEO: MMAI biomarker shows prognostic abilities in prostate cancer
In this video, Paul Nguyen, MD, a genitourinary radiation oncologist at Dana-Farber Cancer Institute, discusses the MMAI trial presented at ASCO Genitourinary Cancers Symposium.
The study examined the multimodal artificial intelligence prognostic biomarker (MMAI, Artera) in high-risk prostate cancer, and tested its prognostic abilities.
“I think it was a fantastic validation of the Artera biomarker, and it will be incredibly important moving forward,” Nguyen said.
Reference:
- Esteva A, et al. Development and validation of a prognostic AI biomarker using multi-modal deep learning with digital histopathology in localized prostate cancer on NRG Oncology phase III clinical trials. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2023; San Francisco.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Nguyen reports consulting for Bayer, Blue Earth Diagnostics, Boston Scientific, Janssen Oncology and Myovant Sciences, and receiving research funding from Astellas Pharma, Bayer and Janssen.
Read more about